Vanda Pharmaceuticals (VNDA) announced that the U.S. FDA has approved Bysanti tablets, a first line therapy for the acute treatment of manic or mixed episodes associated with bipolar I disorder and for the treatment of schizophrenia in adults. Vanda anticipates commercial availability of Bysanti in Q3 of 2026. Bysanti marketing exclusivity is expected to be protected by regulatory data exclusivity and issued U.S. patents, with the latest expiring in 2044, providing a robust foundation for long-term innovation and patient benefit.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VNDA:
- Vanda trading halted, news pending
- Vanda Board Approves 2025 Bonuses and 2026 Compensation
- FDA Calendar: Vanda Stock (VNDA) Shows 125% Upside with Bysanti Decision on Deck
- Regulatory Hurdles Cloud Vanda Pharmaceuticals’ Prospects for Bysanti and Imsidolimab FDA Approvals
- Vanda Pharmaceuticals Balances Growth With Rising Risks